Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Published 2018 View Full Article

Authors

Keywords

Journal

Lancet HIV

Volume 5, Issue 1, Pages e23-e34

Publisher

Elsevier BV

Online

2017-10-12

DOI

10.1016/s2352-3018(17)30179-0

Ask authors/readers for more resources

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

Lancet HIV

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Become a Peeref-certified reviewer

Ask a Question. Answer a Question.